STEM CELLS

CELL THERAPY

GENE THERAPY

TECHNOLOGY

Regenerative medicine based on cultures of epithelial stem cells

Holostem is a commercial stage biotech company entirely devoted to development, manufacture, registration and distribution of Advanced Therapies Medicinal Products (ATMPs) with a focus on cultures of epithelial stem cells both for cell and gene therapy.

MISSION

To promote epithelial stem cell-based Regenerative Medicine for patients with no alternative therapeutic solutions.

Holostem is located into the Centre for Regenerative Medicine “Stefano Ferrari” of the University of Modena and Reggio Emilia.

STEM CELLS

CELL THERAPY

GENE THERAPY

TECHNOLOGY

European Commission approves Holostem project on cell and gene therapy as one of the Important Project of Common European Interest

On the 28th May 2024, European Commission approves Holostem project on cell and gene therapy as one of the Important Project of Common European Interest in the health sector (IPCEI…

05Apr 24

On 22 February 2024, the European Medicines Agency ratified transition of Holoclar from conditional to full Marketing Authorisation

On 22 February 2024, the European Commission ratified, with decision no. 1299 (2024) the passage of the European marketing authorization for Holoclar, cell therapy for the orphan designation of Limbal…